Should I buy or sell Edgewise Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EWTX shares. View EWTX analyst ratings or view top-rated stocks .

What is Edgewise Therapeutics' stock price target for 2024?

5 equities research analysts have issued 12-month price targets for Edgewise Therapeutics' shares. Their EWTX share price targets range from $25.00 to $48.00. On average, they anticipate the company's share price to reach $31.20 in the next year. This suggests a possible upside of 56.0% from the stock's current price. View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts .

How have EWTX shares performed in 2024?

Edgewise Therapeutics' stock was trading at $10.94 at the beginning of the year. Since then, EWTX stock has increased by 82.8% and is now trading at $20.00. View the best growth stocks for 2024 here .

Are investors shorting Edgewise Therapeutics?

Edgewise Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,720,000 shares, an increase of 27.7% from the March 15th total of 4,480,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 9.1% of the company's shares are short sold. View Edgewise Therapeutics' Short Interest .

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its earnings results on Thursday, February, 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.03.

What ETFs hold Edgewise Therapeutics' stock?

ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and ALPS Medical Breakthroughs ETF (SBIO) . iShares U.S. Pharmaceuticals ETF (IHE) .

When did Edgewise Therapeutics IPO?

Edgewise Therapeutics (EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.08%), Swiss National Bank (0.07%), Quantum Private Wealth LLC (0.07%), Denali Advisors LLC (0.02%), China Universal Asset Management Co. Ltd. (0.02%) and Mirae Asset Global Investments Co. Ltd. (0.02%). Insiders that own company stock include Alan J Russell , Behrad Derakhshan, Holdings A/S Novo, Joanne M Donovan, John R Moore, Jonathan C Fox, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers. View institutional ownership trends .

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free EWTX Stock Alerts

$20.00

-0.89 (-4.26%)

(As of 05/9/2024 ET)

Compare

Today's Range: $19.39
▼
$20.83
50-Day Range: $15.08
▼
$21.23
52-Week Range: $5.12
▼
$21.60

Volume: 1.03 million shs
Average Volume: 900,873 shs
Market Capitalization: $1.86 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.20

Get Edgewise Therapeutics alerts:

Edgewise Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 56.0% Upside
$31.20 Price Target
Short Interest: Bearish
9.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.07
Based on 16 Articles This Week
Insider Trading: Selling Shares
$239,495 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.76) to ($1.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.30 out of 5 stars

Medical Sector

721st out of 915 stocks

Pharmaceutical Preparations Industry

339th out of 426 stocks

3.5

Analyst's Opinion

Consensus Rating
Edgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Edgewise Therapeutics has only been the subject of 4 research reports in the past 90 days.
Read more about Edgewise Therapeutics' stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
9.15% of the float of Edgewise Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Edgewise Therapeutics has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Edgewise Therapeutics has recently increased by 0.70%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Edgewise Therapeutics does not currently pay a dividend.
Dividend Growth
Edgewise Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EWTX.

1.7

News and Social Media Coverage

News Sentiment
Edgewise Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Edgewise Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $239,495.00 in company stock.
Percentage Held by Insiders
31.95% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Read more about Edgewise Therapeutics' insider trading history.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.76) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Edgewise Therapeutics is -12.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Edgewise Therapeutics is -12.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Edgewise Therapeutics has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EWTX Stock News Headlines

May 4, 2024 | insidertrades.com

Insider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells 1,718 Shares of Stock

May 9, 2024 | investorplace.com

EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024

May 10, 2024 | InvestorPlace (Ad)

Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”